Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as Monotherapy in Advanced KRAS-Mutant Solid Tumours.

advanced or metastatic kras-mutant tumor in pancreatic adenocarcinoma, advanced or metastatic kras-mutant tumor in colorectal cancer, advanced or metastatic kras-mutant tumor in non small cell lung cancer, advanced solid tumors, advanced or metastatic kras-mutant tumor, antineoplastic agents, pancreatic cancer, colorectal cancer, kras mutation-related tumors, lung cancer, carcinoma, non-small cell lung cancer, non-small cell lung cancer